In a new study, researchers have discovered that certain receptors found on T cells (a type of lymphocyte) can recognize a protein known as viral polymerase in the SARS-CoV-2 virus.
Scientists from the University of Pennsylvania School of Medicine have reported that a drug known as diABZI, showed potent activity against the SARS-CoV-2, including the South African variant B.1.351, a Variant of Concern.
Covid-19 breath test could give you results in 60 seconds
Finding a powerful drug and an efficient method to deliver it, has been the biggest challenge in the development of a faultless therapeutic strategy to combat COVID-19. Providing a potential treatment option, a new study has shown that inhalable nanobodies that target the SARS-CoV-2 coronavirus spike protein can help prevent and treat severe cases of the disease.
Scientists from the University of Pittsburgh, using a hamster model, demonstrated that low doses of an inhalable (or aerosolized) nanobody called Pittsburgh inhalable Nanobody-21 (PiN-21) can prevent and treat acute COVID-19. This is the first time that the nanobodies which are similar to monoclonal antibodies (only smaller in size and more stable) have been tested for treatment via inhalation against coronavirus infections in a pre-clinical model.
A study by researchers from Keck School of Medicine of USC is the first to experimentally demonstrate that GRP78, a molecular chaperone, plays a crucial role in the invasion of human cells by the SARS-CoV-2 coronavirus and its variants.